Inventor · disambiguated record
Gilles Pages
Also filed as: PAGES GILLES
2 granted patents·8 pending applications·0 citations·filing 2012–2022
23Inventor score
Files withCENTRE NAT RECH SCIENT5INST NAT SANTE RECH MED2CENTRE NATIONAL DE LA RECH CNRS1PAGES GILLES1UNIV AIX MARSEILLE1
Top patents by PatentIndex Score
10 records- 0151US2024316005A1Gene signatures for predicting survival time in patients suffering from renal cell carcinomaINST NAT SANTE RECH MED·Filed 2022·Application pending·0 cites
- 0249US2024199562A1Urea derivatives for treating uveal melanomaCENTRE NAT RECH SCIENT·Filed 2022·Application pending·0 cites
- 0348US2025346642A1New splice variant isoform of vegfCENTRE NAT RECH SCIENT·Filed 2021·Application pending·0 cites
- 0442US2021380547A1Urea derivatives for treating and/or preventing cancerCENTRE NAT RECH SCIENT·Filed 2019·Application pending·0 cites
- 0539US2022137054A1New biomarkers and biotargets in renal cell carcinomaINST NAT SANTE RECH MED·Filed 2020·Application pending·0 cites
- 0638US2020232989A1Methods and kits for predicting the sensitivity of a subject suffering of renal cancer to sunitinibUNIV AIX MARSEILLE·Filed 2018·Application pending·0 cites
- 0732US2023192833A1New anti-VEGFC antibodies and uses thereofCENTRE NATIONAL DE LA RECH CNRS·Filed 2021·Application pending·0 cites
- 0830US10047156B2Anti-CXCL1, CXCL7 and CXCL8 antibodies and their applicationsCENTRE NAT RECH SCIENT·Filed 2014·Granted Aug 14, 2018·0 cites·10 claims
- 0926US9567627B2Method for predicting the response to treatment with an HER2-blocking agentPAGES GILLES·Filed 2012·Granted Feb 14, 2017·0 cites·3 claims
- 1024US2019195880A1Methods and kits for predicting the sensitivity of a subject suffering of renal cancer to cancer treatmentCENTRE NAT RECH SCIENT·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Gilles Pages files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →